SEC Tracker
Get the app
ZTS · XBRL financial data

Zoetis financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ZTS's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue2,1512,213*2,1902,3612,3882,317*2,2202,4602,4002,387*2,2622,468
Cost of goods and services sold638728*643668701707*622649683712*641673
Selling, general and administrative525565*547581565625*563617579619*588592
Interest expense5959*58595751*54535857*6261
Other income (expense)(4)5*(7)1(4)6*3(1)0(8)*(1)(2)
Income tax expense (benefit)121127*148156182151*179184166158*157175
Net income (loss)596525*599624682581*631718721603*601691
Earnings per share, basic USD per share1.291.14*1.311.371.511.29*1.411.611.631.38*1.421.65
Earnings per share, diluted USD per share1.291.14*1.311.371.501.29*1.411.611.631.37*1.421.65
Weighted average shares, basic millions of shares460459*458456453450*448445443438*422418
Weighted average shares, diluted millions of shares461460*459456454451*448446443439*422418

Balance sheet

CSV

Fiscal quarters (ZTS's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents1,7542,0411,9751,5741,7141,9871,7211,4352,0842,4501,9411,476
Short-term investments—————————0—200
Accounts receivable1,2571,3041,2931,3831,4111,3161,3611,5401,5411,5901,5061,571
Inventory2,7442,5642,6512,4522,4162,3062,3652,4392,4652,4302,5502,574
Total current assets6,2226,3436,3596,2026,2825,9865,8775,9236,5836,7686,4746,356
Property and equipment, net3,0923,2043,2513,2003,2983,3913,4413,5373,6003,6813,7193,756
Right-of-use asset226230225222223219220302292288282275
Goodwill2,7622,7592,7592,7392,7442,7242,7162,7582,7642,7672,7782,771
Total assets14,10614,28614,34814,16514,35714,23714,09814,47915,15915,46715,15415,077
Accounts payable388411405420404433420508410487507452
Accrued liabilities—683———746———852——
Commercial paper000000000000
Current portion of long-term debt00———1,3501,3501,35000——
Total current liabilities1,6081,8891,9091,7971,7023,4123,3853,3661,8072,2352,0532,061
Long-term debt6,5526,5646,5626,5636,5745,2205,2275,2317,0699,0429,0459,048
Lease liability, non-current191188184181181174173210204196193190
Total liabilities9,0329,2959,2969,2059,1239,4679,4439,5029,76112,13611,92111,929
Retained earnings10,14010,29510,69611,12411,80611,96812,37512,87213,59313,74414,18314,653
Total stockholders' equity5,0784,9975,0584,9665,2344,7704,6554,9775,3983,3313,2333,148
Total liabilities and equity14,10614,28614,34814,16514,35714,23714,09814,47915,15915,46715,15415,077
Common shares outstanding (cover page) millions of shares459458456453451448445443441422419413

Cash flows

CSV

Fiscal quarters (ZTS's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)596525*599624682581*631718721603*601691
Stock-based compensation17*17*1819*18*19*1722*22*22*2526*
Depreciation and amortization124126*126127121123*119123124121*119119
Net cash from operating activities724*897*595502*951*905*587486*938*893*401655*
Purchases of property and equipment145*198*140132*167*216*149178*133*161*110117*
Net cash from investing activities(271)*(210)*(131)(132)*(178)*126*(175)(247)*(160)*(166)*(87)(300)*
Share repurchases250*235*339533*433*553*443338*394*2,060*606584*
Repayments of long-term debt0*0*00*0*0*———0*——
Net cash from financing activities(416)*(397)*(524)(763)*(628)*(745)*(677)(564)*(134)*(495)*(840)(813)*
Net change in cash37*287*(66)(401)*140*273*(266)(286)*649*228*(509)(465)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingQuarter
Zoetis1,4762,468655*413.2M 10-QJun 30, 2026
Regeneron Pharmaceuticals3,6595,1161,783*not reported 10-QSep 30, 2026
Bristol Myers Squibb9,57413,0694,181*2.0B 10-QSep 30, 2026
Gilead Sciences6,4378,3005,035*1.2B 10-QSep 30, 2026
Idexx Laboratories1981,214450*78.8M 10-QSep 30, 2026
Alnylam Pharmaceuticals1,7541,458341*133.9M 10-QSep 30, 2026
Vertex Pharmaceuticals4,9793,441643*253.5M 10-QSep 30, 2026
Pfizer1,82416,5835,375*5.7B 10-QSep 27, 2026
Amgen13,19010,3654,241*540.9M 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.